Part 4/6:
During the discussion, the analysts speculated on Starbucks’ strategy in China and whether the company needs to hit aggressive targets or if coming close might suffice. Argersinger expressed optimism, believing that if they manage revenue well per store while expanding, they will maintain healthy overall sales figures.
Celgene: A Biotech Powerhouse
Jeff Fischer introduced Celgene (CELG), a biotechnology titan with a market capitalization of $84 billion, primarily known for its cancer treatment drugs. Fischer discussed the company’s recent success in securing patent protection for its leading drug until at least 2022, which he claims is central to sustaining profit margins against upcoming generic competition.